Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
Key Highlights
- ➤Eupraxia establishes ATM program for up to US$125 million in common shares
- ➤Cash runway guidance unchanged, covering planned expenses until H2 2028
- ➤Company says it has no current plan to use the ATM near term
- ➤ATM shares would sell at prevailing market prices through Jefferies agents
Expert Statements
Alex Rothwell, Chief Financial Officer of Eupraxia Pharmaceuticals
“The ATM Program has been put in place as a general corporate housekeeping item, consistent with industry norms”
VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that it has entered into a sales agreement (the “ATM Sales Agreement”) with Jefferies LLC (the “U.S. Agent”) and Jefferies Securities, Inc. (the “Canadian Agent”, and together with the U.S. Agent, the “Agents”), thereby establishing an at-the-market equity program (the “ATM Program”).
"The ATM Program has been put in place as a general corporate housekeeping item, consistent with industry norms” said Alex Rothwell, Chief Financial Officer of Eupraxia. “As outlined in our just-released quarterly financials, guidance on cash runway remains unchanged, with current cash balances covering the company's planned expenses until H2 2028. Accordingly, the Company has no current plan to use the ATM Program in the near term."
Get started
Create a free account to read the full story.